Investor Lawsuits Target Inspire Medical Over Inspire V Rollout as Firms Seek Lead Plaintiff

Plaintiffs cite an August 4 guidance cut with a 32% stock drop tied to alleged rollout failures.

Overview

Hagens Berman, Portnoy Law Firm, and Glancy Prongay & Murray issued new notices inviting INSP investors to pursue lead-plaintiff roles by Jan. 5, 2026.
Hagens Berman says the lawsuit is pending in the U.S. District Court for the District of Minnesota.
Complaints allege Inspire promoted operational readiness while Medicare claims software was not updated until July 1, 2025, preventing early billing for procedures.
Filings assert a surplus of the prior Inspire IV device at customers depressed demand for the new Inspire V.
On Aug. 4, 2025, the company extended the rollout, cut 2025 EPS guidance by more than 80%, and shares fell roughly 32% or about $42 per share.